|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Wild-type mice, atherosclerotic mice with double knockout (DKO) of the low-density lipoprotein receptor and Apobec-1, and DKO mice treated with the Nox-inhibitor apocynin were studied at baseline and at 3 and 21 days after closed-chest MI.
|
30139430 |
2018 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Whereas Ldlr(-/-)Apobec1(-/-) mice fed a western-type diet and injected with a control AAV8.null vector experienced a further 65% progression in atherosclerosis over 2 months compared with baseline mice, Ldlr(-/-)Apobec1(-/-) mice treated with AAV8.mLDLR realized an 87% regression of atherosclerotic lesions after 3 months compared to baseline mice.
|
20976059 |
2010 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Whereas Ldlr(-/-)Apobec1(-/-) mice fed a western-type diet and injected with a control AAV8.null vector experienced a further 65% progression in atherosclerosis over 2 months compared with baseline mice, Ldlr(-/-)Apobec1(-/-) mice treated with AAV8.mLDLR realized an 87% regression of atherosclerotic lesions after 3 months compared to baseline mice.
|
20976059 |
2010 |
|
Epilepsy, Temporal Lobe
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Together, these results demonstrate Apobec-1-dependent expression of RNA-edited GlyR protein in neurons and identify the <i>APOBEC1</i> 80I/M-coding alleles as new genetic risk factors for iTLE patients.
|
29375302 |
2017 |
|
Cholelithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate APOBEC1 and PPARG as candidate genes for common symptomatic gallstone disease in humans.
|
17696929 |
2007 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
This reduced tumor burden was found in association with increased small intestinal apoptosis and reduced proliferation in small intestinal crypt-villus units from compound Apc(min/+) apobec-1(-/-) mice.
|
17875695 |
2007 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
This includes the repression of a network of GTPase-related genes (Prkg1, Gnao1 and Rgs9) in tumor samples and an enrichment of Apobec1-mediated cytosine to uridine RNA editing.
|
24317514 |
2015 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
These results indicates that long-term hepatic expression of APOBEC-1 at low levels sufficient to eliminate LDL does not cause apparent liver damage or liver tumors in transgenic mice.
|
9633945 |
1998 |
|
Intestinal adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that deletion of apobec-1, by modulating expression of AU-rich RNA targets, provides an important mechanism for attenuating a dominant genetic restriction point in intestinal adenoma formation.
|
17875695 |
2007 |
|
Middle Cerebral Artery Occlusion
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Then the correlation of Apobec-1 level and injury severity was analyzed in cells with oxygen-glucose deprivation and in rats with middle cerebral artery occlusion.
|
23609497 |
2013 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The transgene expression of the catalytic subunit APOBEC-1 of the apo B mRNA editing enzyme-complex can cause hepatocellular carcinoma in mice and rabbits.
|
10597235 |
1999 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The correlation of APOBEC1 expression levels with cancer indels was independent of age and defects in DNA homologous recombination (HR) and/or mismatch repair.
|
29346513 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The correlation of APOBEC1 expression levels with cancer indels was independent of age and defects in DNA homologous recombination (HR) and/or mismatch repair.
|
29346513 |
2018 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The 'auxiliary' components of the apo B mRNA editing enzyme-complex are missing in many tumors including colorectal and gastric carcinoma, but are highly expressed in hepatocellular, lung adeno- and breast carcinoma all of which lack APOBEC-1.
|
10597235 |
1999 |
|
Neurofibromatosis 1
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
Taken together, the data support the hypothesis that C-->U RNA editing of the NF1 transcript occurs both in a subset of PNSTs and in an alternatively spliced form containing a downstream exon, presumably an optimal configuration for enzymatic deamination by apobec-1.
|
11727199 |
2002 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Such APOBEC1-induced mutator phenotypes could play a role in the onset of esophageal adenocarcinomas.
|
25085003 |
2014 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
RE4 APOBEC-1 transgenic mice should prove valuable for studying the roles of apoB-containing lipoproteins in lipid metabolism and atherosclerosis.
|
9633945 |
1998 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
RE4 APOBEC-1 transgenic mice should prove valuable for studying the roles of apoB-containing lipoproteins in lipid metabolism and atherosclerosis.
|
9633945 |
1998 |
|
Complex partial seizures
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Patients with expression of the Apobec-1 80I variant mostly suffered from simple or complex partial seizures, whereas patients with 80M expression exhibited secondarily generalized seizure activity.
|
29375302 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Overexpression of APOBEC-1 in transgenic animals caused liver dysplasia and APOBEC-1 has been identified in neurofibromatosis type 1 tumours, suggesting that RNA editing may be another mechanism for tumourigenesis.
|
11072063 |
2000 |
|
Neurofibromatosis 1
|
0.020 |
Biomarker
|
disease |
BEFREE |
Overexpression of APOBEC-1 in transgenic animals caused liver dysplasia and APOBEC-1 has been identified in neurofibromatosis type 1 tumours, suggesting that RNA editing may be another mechanism for tumourigenesis.
|
11072063 |
2000 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Murine APOBEC1 was able to hyperdeaminate cytidine residues in murine leukemia virus genomic RNA as well.
|
18983852 |
2009 |
|
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Murine APOBEC1 was able to hyperdeaminate cytidine residues in murine leukemia virus genomic RNA as well.
|
18983852 |
2009 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Moreover, we find the presence of an AID/APOBEC mutational signature in esophageal adenocarcinomas, a type of tumor where APOBEC1 is expressed, that mimics the one preferred by APOBEC1 in vitro.
|
25085003 |
2014 |